Guardant360® is the first clinically available, validated, comprehensive liquid biopsy
Guardant360® is the first clinically validated comprehensive liquid biopsy that is available.
This test was validated in detail and published for clinical use. Moreover Guardant360® is the only comprehensive test with clinical results. There are numerous publications about Guardant360®.
Guardant Health also regularly takes part in expert conferences and presents latest findings.
Using the following link you can reach the up-to-date publications.
Selected publications about Guardant360®
- Kim et al. (2017) (http://ascopubs.org/doi/abs/10.1200/PO.16.00059) demonstrated in a prospective stuy the clinical benefit of Guardant360® for advanced solid tumors. Patients treated according to test result had a better outcome.
- Schwaederlé et al. (2017) (http://clincancerres.aacrjournals.org/content/early/2017/05/24/1078-0432.CCR-16-2497) demonstrated that a therapy adjusted to the alterations of the ctDNA leads to therapeutic efficacy.
- Liang et al. (2016) (https://link.springer.com/article/10.1007/s10549-015-3635-5) demonstrated that ctDNA can be used to monitor the response and the disease progress.
- Lanman et al. (2015) (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608804/) describe the analytical and clincial validation of the gene panel which is used for ctDNA evaluation. With digital sequencing that is used for Guardant360® a analytical specificity of 99.9999 % is achieved and almost all false-positive results are eliminated